DE60214527D1 - Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit - Google Patents

Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit

Info

Publication number
DE60214527D1
DE60214527D1 DE60214527T DE60214527T DE60214527D1 DE 60214527 D1 DE60214527 D1 DE 60214527D1 DE 60214527 T DE60214527 T DE 60214527T DE 60214527 T DE60214527 T DE 60214527T DE 60214527 D1 DE60214527 D1 DE 60214527D1
Authority
DE
Germany
Prior art keywords
flumazenil
alcohol dependence
medicament
development
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60214527T
Other languages
English (en)
Other versions
DE60214527T2 (de
Inventor
Ibanez Juan Jose Legarda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catasys Inc
Original Assignee
Catasys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catasys Inc filed Critical Catasys Inc
Application granted granted Critical
Publication of DE60214527D1 publication Critical patent/DE60214527D1/de
Publication of DE60214527T2 publication Critical patent/DE60214527T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60214527T 2001-01-17 2002-01-10 Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit Expired - Lifetime DE60214527T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200100106 2001-01-17
ES200100106 2001-01-17
PCT/ES2002/000008 WO2002056964A1 (es) 2001-01-17 2002-01-10 Empleo de flumazenilo en la elaboración de una medicación para el tratamiento de la dependencia de alcohol

Publications (2)

Publication Number Publication Date
DE60214527D1 true DE60214527D1 (de) 2006-10-19
DE60214527T2 DE60214527T2 (de) 2007-04-05

Family

ID=8496426

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214527T Expired - Lifetime DE60214527T2 (de) 2001-01-17 2002-01-10 Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit

Country Status (23)

Country Link
US (2) US7348321B2 (de)
EP (1) EP1374952B1 (de)
JP (2) JP2004519461A (de)
KR (1) KR100712570B1 (de)
CN (1) CN1486205A (de)
AT (1) ATE338575T1 (de)
AU (1) AU2002226427B2 (de)
BR (1) BR0206549A (de)
CA (1) CA2433833C (de)
CR (1) CR7049A (de)
CY (1) CY1107500T1 (de)
DE (1) DE60214527T2 (de)
DK (1) DK1374952T3 (de)
ES (1) ES2269661T3 (de)
HK (1) HK1061661A1 (de)
IL (1) IL156798A0 (de)
MX (1) MXPA03006411A (de)
NZ (2) NZ527583A (de)
PT (1) PT1374952E (de)
RU (1) RU2300378C2 (de)
UA (1) UA78199C2 (de)
WO (1) WO2002056964A1 (de)
ZA (1) ZA200305922B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20060172998A1 (en) * 2005-02-03 2006-08-03 Halikas James A Method of preventing relapse in the abstinent substance dependent individual
US20060172996A1 (en) * 2005-02-03 2006-08-03 Halikas James A Method of preventing relapse in the abstinent substance dependent individual
EP1868593A2 (de) 2005-04-07 2007-12-26 Hythiam, Inc. Verbesserte verfahren und zusammensetzungen zur prävention von angstzuständen, substanzenmissbrauch und abhängigkeit
US20060263304A1 (en) * 2005-05-23 2006-11-23 Halikas James A Method of controlling alcohol intake and reversing alcohol effects
AU2008283903B2 (en) 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
EP2186517A4 (de) * 2007-08-08 2010-08-18 Ibanez Juan Jose Legarda Verwendung und anwendungsverfahren für einen serotin3-rezeptor (5-ht3)-antagonisten und selektiven chloridkanalmodulator zur behandlung von sucht bzw. abhängigkeit von arzneimitteln/drogen oder erkrankungen des nervensystems
US9283212B2 (en) 2009-02-20 2016-03-15 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20100280684A1 (en) * 2009-04-29 2010-11-04 Pierre Garon Synchronization of shift and throttle controls in a marine vessel
US8347859B2 (en) * 2009-04-29 2013-01-08 Marine Canada Acquisition Inc. Automatic throttle calibration in a marine vessel
US8387589B2 (en) * 2009-04-29 2013-03-05 Marine Canada Acqusition Inc. Position sensor for an output shaft used in a shift and throttle system
US8930050B2 (en) * 2009-04-29 2015-01-06 Marine Canada Acquisition Inc. Method and system for increasing or decreasing engine throttle in a marine vessel
US8845490B2 (en) 2010-02-10 2014-09-30 Marine Canada Acquisition Inc. Method and system for delaying shift and throttle commands based on engine speed in a marine vessel
US8406944B2 (en) * 2010-02-10 2013-03-26 Pierre Garon Control system and method for starting and stopping marine engines
US8182396B2 (en) * 2010-02-10 2012-05-22 Marine Canada Acquisition In.c Method and system for delaying shift and throttle commands based on engine speed in a marine vessel
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Also Published As

Publication number Publication date
AU2002226427B2 (en) 2006-11-16
US7348321B2 (en) 2008-03-25
CA2433833A1 (en) 2002-07-25
CN1486205A (zh) 2004-03-31
PT1374952E (pt) 2006-12-29
US20080132492A1 (en) 2008-06-05
DK1374952T3 (da) 2007-01-02
KR100712570B1 (ko) 2007-05-02
JP2004519461A (ja) 2004-07-02
RU2003125274A (ru) 2005-01-20
KR20040020046A (ko) 2004-03-06
UA78199C2 (en) 2007-03-15
BR0206549A (pt) 2004-02-25
CY1107500T1 (el) 2013-03-13
DE60214527T2 (de) 2007-04-05
ES2269661T3 (es) 2007-04-01
EP1374952B1 (de) 2006-09-06
RU2300378C2 (ru) 2007-06-10
IL156798A0 (en) 2004-02-08
CR7049A (es) 2008-02-20
JP2008201796A (ja) 2008-09-04
US20040092509A1 (en) 2004-05-13
WO2002056964A1 (es) 2002-07-25
MXPA03006411A (es) 2004-12-02
ZA200305922B (en) 2004-08-02
CA2433833C (en) 2009-06-02
ATE338575T1 (de) 2006-09-15
HK1061661A1 (en) 2004-09-30
NZ539400A (en) 2006-04-28
NZ527583A (en) 2006-03-31
EP1374952A1 (de) 2004-01-02

Similar Documents

Publication Publication Date Title
CY1107500T1 (el) Η χρηση του φλουμαζενιλ στην αναπτυξη ενος φαρμακου για τη θepαπευτικη αντιμετωπιση της εξαρτησης απο το αλκοολ
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
ATE296640T1 (de) Methode und mittel zur behandlung eines post- poliosyndroms
DE60003921D1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ATE266403T1 (de) Verwendung von 2-methyl-thiazolidin 2,4- dicarbonsäure zur herstellung eines medikaments zur behandlung von infektionskrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition